Investigational drug · Phase 3
VYD2311-SD
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for COVID-19.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "VYD2311-SD"
First trial start
2026
Jan 8, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VYD2311-SD", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19
Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VYD2311-SD" as an intervention, largest first.
- Study of VYD2311 for the Prevention of COVID-19Pivotal-lookingActive, not recruiting
Invivyd, Inc.Industry
NCT07298434 · 1,770 participants (planned) · Start Jan 8, 2026 · Primary completion Aug 2026
Drug: VYD2311-SD; VYD2311-MD and 1 more · For: COVID-19
Sites: Long Beach, California; San Diego, California; Orlando, Florida · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for COVID-19
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- VYD2311Phase 32 trials
Invivyd, Inc. · Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine
- DAS181Phase 31 trial
Ansun Biopharma, Inc. · Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised
- SCTA01Phase 31 trial
Sinocelltech Ltd. · COVID-19, SARS-CoV-2
- VYD222pemivibartPhase 31 trial
Invivyd, Inc. · COVID-19, SARS-CoV-2
- VYD2311-MDPhase 31 trial
Invivyd, Inc. · COVID-19
- CVXGACVXGA50, PIV5-SARS CoV-2Phase 22 trials
CyanVac LLC · COVID-19
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.